+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 47 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments to prevent non-small cell lung cancer NSCLC from returning after surgery in people with high-risk, localized Stage I NSCLC. This Phase 3 randomized clinical trial compares adjuvant intismeran autogene V940 alone or combined with subcutaneous pembrolizumab and berahyaluronidase alfa against placebo in participants who have had their cancer completely removed. The goal is to improve disease-free survival in these patients. Participants are assigned to one of three groups one receives intismeran 1 mg by intramuscular injection plus pembrolizumab with berahyaluronidase alfa by subcutaneous injection another group receives intismeran alone by intramuscular injection and the third group receives a placebo injection. Treatments are given as part of the study, with dosing schedules and combinations designed to evaluate their effects on cancer recurrence. During the study, participants will be closely monitored through regular assessments including imaging scans and laboratory tests to track disease status and side effects. Researchers will measure outcomes such as disease-free survival, distant metastasis-free survival, overall survival, and quality of life using standardized questionnaires. Safety will also be monitored throughout the study, which may last up to several years for some participants.

Age: 18Years +All GendersPhase 3
124 locations
R

Actively Recruiting

Researchers are evaluating BNT324 compared to the standard chemotherapy docetaxel combined with prednisone or prednisolone in men with metastatic castration-resistant prostate cancer mCRPC who have been previously treated with androgen receptor pathway inhibitors but have not received taxane-based chemotherapy for mCRPC. This phase III trial aims to determine if BNT324 can help participants live longer without their cancer worsening and improve overall survival. Participants are randomly assigned to one of two groups receiving BNT324 through intravenous infusion or receiving docetaxel intravenously along with oral prednisone or prednisolone. Treatment is given in 21-day cycles and continues until the cancer progresses, side effects become unacceptable, the participant decides to stop, or the study concludes. The study includes a screening period lasting up to 28 days, followed by treatment and an after-treatment period that includes a 30-day safety follow-up and a long-term survival follow-up. Participants will undergo assessments including scans reviewed centrally to monitor cancer progression, laboratory tests such as PSA levels, and evaluation of side effects. Researchers will track outcomes like radiographic progression-free survival and overall survival for up to approximately 58 months. Safety is closely monitored by an independent committee, and participants continue regular follow-up visits during and after treatment to assess response and manage any adverse events.

Age: 18Years +MALEPhase 3
52 locations
P

Actively Recruiting

Researchers are studying the effects of Problem Adaptation Therapy for Pain PATH-Pain on older adults who have mild cognitive impairment MCI or early Alzheimers disease AD, along with depression and chronic pain. The study compares PATH-Pain with usual care that includes medical attention and educational sessions. The goal is to see if PATH-Pain improves thinking abilities, mood, and daily functioning more than standard care. Participants in the PATH-Pain group will receive eight weekly in-person therapy sessions during the first two months, followed by six monthly phone sessions including individual and group calls from months 3 to 9. Each session lasts about 50 minutes. The usual care group will continue their medical treatment and receive similar numbers of educational and interview sessions. PATH-Pain may also involve using a tablet app to help with emotion regulation and may include caregiver involvement. Participants will be assessed at the start and at several points up to one year to measure changes in cognitive function, depression symptoms, and pain-related disability. Assessments include interviews and standardized tests such as the Repeatable Battery for the Assessment of Neuropsychological Status RBANS. The study is led by Weill Medical College of Cornell University and focuses on treatments delivered in primary care settings by certified mental health clinicians.

Age: 60Years +All GendersPhase Not Applicable
1 location
G

Actively Recruiting

Researchers are evaluating the safety and clinical activity of EIK1001, a drug that targets Toll like receptor 78, given intravenously with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer NSCLC. This global, multicenter, double-blind, placebo-controlled study involves participants who have not received prior systemic therapy and aims to assess treatment effects in both squamous and non-squamous NSCLC types. The trial is conducted in two phases Phase 2 and Phase 3 and includes dose optimization, dose expansion, and confirmatory hypothesis testing. Participants are randomly assigned to one of three groups EIK1001 at one of two selected doses plus standard chemotherapy and pembrolizumab, or placebo plus standard chemotherapy and pembrolizumab. Chemotherapy regimens differ based on tumor histology, with pemetrexed plus carboplatin or cisplatin for non-squamous NSCLC, and carboplatin plus paclitaxel or nab-paclitaxel for squamous NSCLC. Treatments are administered intravenously, and the study is designed to evaluate safety and efficacy over time. During the study, participants undergo regular assessments to monitor progression-free survival, overall survival, and objective response, which are tracked for up to 6 to 10 years depending on the measure. Additional evaluations include adverse event incidence and duration of response. Participants are monitored closely with clinical visits throughout the study period, which may last several years, to ensure safety and collect data on treatment effects.

Age: 18Years +All GendersPhase 2Phase 3
42 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a chemotherapy payload, compared to treatment chosen by physicians including paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine for patients with first-line metastatic triple-negative breast cancer TNBC or low estrogen receptor ER-low, HER2-negative breast cancer who cannot receive anti-PDL1 or endocrine therapies. This study includes adults with locally advanced, recurrent inoperable, or metastatic disease who meet specific eligibility criteria. Participants are randomly assigned to receive iza-bren or one of the physicians choice chemotherapy regimens. The treatments are given at specified doses on scheduled days. The study includes two phases Phase 2 to determine the recommended dose of iza-bren and Phase 3 to compare progression-free survival and other outcomes. The study will last several years, with follow-up extending up to approximately 47 months after randomization. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests, and monitoring for adverse events. Quality of life questionnaires will also be completed. Researchers will track progression-free survival, overall survival, treatment-related side effects, tumor size changes, and patient-reported outcomes to evaluate the treatments. The total participation duration may extend up to several years depending on treatment response and follow-up requirements.

Age: 18Years +All GendersPhase 2Phase 3
295 locations
R

Actively Recruiting

Researchers are evaluating treatments for participants with metastatic colorectal cancer mCRC who have previously received irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab. The study aims to compare overall survival when using precemtabart tocentecan Precem-TcT alone, Precem-TcT combined with bevacizumab, and trifluridinetipiracil FTD-TPI plus bevacizumab. This Phase 3 trial addresses the unmet need for effective treatment options in this patient group. Participants will be randomly assigned to one of three groups Precem-TcT alone given intravenously every 3 weeks on Day 1 of each 21-day cycle Precem-TcT combined with bevacizumab administered intravenously every 3 weeks or every 2 weeks depending on the cycle or FTD-TPI tablets taken orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle along with bevacizumab. The study evaluates these treatments over cycles lasting up to an average of 19 months. During the study, participants will undergo various assessments including survival monitoring, disease progression checks, response evaluations using RECIST criteria, adverse event tracking, and quality of life questionnaires. Blood samples will be collected at specific times to measure drug concentrations and immune response markers. Researchers will assess physical functioning and health status repeatedly until treatment ends, with safety and treatment effects monitored throughout the trial period.

Age: 18Years +All GendersPhase 3
92 locations
S

Actively Recruiting

Researchers are evaluating whether adding sacituzumab tirumotecan to pembrolizumab after surgery improves treatment outcomes for adults with resectable non-small cell lung cancer NSCLC who did not achieve a complete response after initial therapy. The study focuses on comparing disease-free survival between participants receiving pembrolizumab alone and those receiving a combination of pembrolizumab and sacituzumab tirumotecan. The trial is a phase 3, randomized, open-label study sponsored by Merck Sharp & Dohme LLC. Participants first receive pembrolizumab combined with platinum-based doublet chemotherapy as neoadjuvant therapy before surgery. After surgery, participants who did not achieve pathological complete response are assigned to one of two groups one group receives sacituzumab tirumotecan every two weeks for up to 12 doses alongside pembrolizumab every six weeks for up to seven cycles, while the other group receives pembrolizumab monotherapy every six weeks for up to seven cycles. The neoadjuvant chemotherapy includes drugs such as cisplatin, pemetrexed, gemcitabine, carboplatin, and paclitaxel, chosen based on tumor histology. Throughout the study, participants will be monitored regularly with assessments including imaging scans to evaluate disease status and quality of life questionnaires. The primary outcome is disease-free survival assessed by blinded independent central review for up to approximately 93 months. Secondary outcomes include overall survival, lung cancer-specific survival, adverse events, and changes in physical functioning and symptoms related to lung cancer. The study duration can last up to nearly 10 years with follow-up visits to monitor health and treatment effects.

Age: 18Years +All GendersPhase 3
270 locations
E

Actively Recruiting

Researchers are evaluating the combination of setidegrasib with chemotherapy in adults who have metastatic pancreatic cancer with a specific KRAS G12D gene mutation. This mutation leads to abnormal proteins that may promote cancer growth. The study aims to find out if adding setidegrasib to standard chemotherapy improves survival compared to chemotherapy with a placebo. This trial is a phase 3, randomized, double-blind study focused on treatment outcomes in this patient population. Participants will receive either setidegrasib or a placebo once weekly along with one of two chemotherapy regimens, mFOLFIRINOX or NALIRIFOX, given in 28-day cycles through intravenous infusion. The choice of chemotherapy is determined by the study doctor. Treatment continues until cancer progression, intolerable side effects, start of other cancer therapies, participant or doctor decision to stop, or death. NALIRIFOX is given only after safety is confirmed with setidegrasib in another study. During the study, participants will have regular safety checks, medical assessments, and evaluations of their wellbeing. Researchers will measure overall survival up to 3.5 years, time to cancer progression, quality of life, pain improvement, response rates, adverse events, and pharmacokinetics of setidegrasib. The study includes extensive monitoring of laboratory values, vital signs, and heart function with electrocardiograms throughout the trial period.

Age: 18Years +All GendersPhase 3
104 locations

1-10 of 47

1